Go Pro
→ Why major institutions are piling into this digital asset now (From Awesomely) (Ad)tc pixel Free BXP Stock Alerts

Beximco Pharmaceuticals (BXP) Competitors

Beximco Pharmaceuticals logo
GBX 54 -1.00 (-1.82%)
As of 08/21/2026 12:13 PM Eastern
Compare

BXP vs. VEC, ERGO, BMY, AMYT, and APH

Should you buy Beximco Pharmaceuticals stock or one of its competitors? Beximco Pharmaceuticals's main competitors and comparable companies include Vectura Group (VEC), Ergomed (ERGO), Bloomsbury Publishing (BMY), Amryt Pharma (AMYT), and Alliance Pharma (APH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Beximco Pharmaceuticals compare to Vectura Group?

Beximco Pharmaceuticals (LON:BXP) and Vectura Group (LON:VEC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

0.3% of Beximco Pharmaceuticals shares are held by institutional investors. 4.2% of Beximco Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Beximco Pharmaceuticals' average media sentiment score of 0.00 equaled Vectura Group'saverage media sentiment score.

Company Overall Sentiment
Beximco Pharmaceuticals Neutral
Vectura Group Neutral

Beximco Pharmaceuticals has higher revenue and earnings than Vectura Group. Vectura Group is trading at a lower price-to-earnings ratio than Beximco Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousand0.03
Vectura Group£190.60M0.00N/A£20.10N/A

Beximco Pharmaceuticals has a net margin of 16.76% compared to Vectura Group's net margin of 0.00%. Beximco Pharmaceuticals' return on equity of 11.99% beat Vectura Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Beximco Pharmaceuticals16.76% 11.99% 6.97%
Vectura Group N/A N/A N/A

Summary

Beximco Pharmaceuticals beats Vectura Group on 7 of the 8 factors compared between the two stocks.

How does Beximco Pharmaceuticals compare to Ergomed?

Beximco Pharmaceuticals (LON:BXP) and Ergomed (LON:ERGO) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

In the previous week, Beximco Pharmaceuticals' average media sentiment score of 0.00 equaled Ergomed'saverage media sentiment score.

Company Overall Sentiment
Beximco Pharmaceuticals Neutral
Ergomed Neutral

Beximco Pharmaceuticals has a net margin of 16.76% compared to Ergomed's net margin of 9.87%. Ergomed's return on equity of 18.08% beat Beximco Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Beximco Pharmaceuticals16.76% 11.99% 6.97%
Ergomed 9.87%18.08%10.16%

Beximco Pharmaceuticals has higher revenue and earnings than Ergomed. Ergomed is trading at a lower price-to-earnings ratio than Beximco Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousand0.03
Ergomed£152.09M0.00£15M£0.29N/A

Beximco Pharmaceuticals has a beta of 0.248, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Ergomed has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market.

0.3% of Beximco Pharmaceuticals shares are held by institutional investors. Comparatively, 71.1% of Ergomed shares are held by institutional investors. 4.2% of Beximco Pharmaceuticals shares are held by insiders. Comparatively, 18.2% of Ergomed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Ergomed beats Beximco Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Beximco Pharmaceuticals compare to Bloomsbury Publishing?

Bloomsbury Publishing (LON:BMY) and Beximco Pharmaceuticals (LON:BXP) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

42.2% of Bloomsbury Publishing shares are held by institutional investors. Comparatively, 0.3% of Beximco Pharmaceuticals shares are held by institutional investors. 3.6% of Bloomsbury Publishing shares are held by company insiders. Comparatively, 4.2% of Beximco Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Bloomsbury Publishing had 1 more articles in the media than Beximco Pharmaceuticals. MarketBeat recorded 1 mentions for Bloomsbury Publishing and 0 mentions for Beximco Pharmaceuticals. Bloomsbury Publishing's average media sentiment score of 0.75 beat Beximco Pharmaceuticals' score of 0.00 indicating that Bloomsbury Publishing is being referred to more favorably in the media.

Company Overall Sentiment
Bloomsbury Publishing Positive
Beximco Pharmaceuticals Neutral

Bloomsbury Publishing presently has a consensus target price of GBX 800, suggesting a potential upside of 22.32%. Given Bloomsbury Publishing's stronger consensus rating and higher probable upside, analysts plainly believe Bloomsbury Publishing is more favorable than Beximco Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bloomsbury Publishing
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Beximco Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Bloomsbury Publishing has a beta of 0.418, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Beximco Pharmaceuticals has a beta of 0.248, suggesting that its share price is 75% less volatile than the broader market.

Beximco Pharmaceuticals has a net margin of 16.76% compared to Bloomsbury Publishing's net margin of 8.28%. Bloomsbury Publishing's return on equity of 12.74% beat Beximco Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Bloomsbury Publishing8.28% 12.74% 7.82%
Beximco Pharmaceuticals 16.76%11.99%6.97%

Beximco Pharmaceuticals has higher revenue and earnings than Bloomsbury Publishing. Beximco Pharmaceuticals is trading at a lower price-to-earnings ratio than Bloomsbury Publishing, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bloomsbury Publishing£325.90M1.62£37.37M£32.8019.94
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousand0.03

Summary

Bloomsbury Publishing beats Beximco Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Beximco Pharmaceuticals compare to Amryt Pharma?

Beximco Pharmaceuticals (LON:BXP) and Amryt Pharma (LON:AMYT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

Beximco Pharmaceuticals has a net margin of 16.76% compared to Amryt Pharma's net margin of 0.00%. Beximco Pharmaceuticals' return on equity of 11.99% beat Amryt Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Beximco Pharmaceuticals16.76% 11.99% 6.97%
Amryt Pharma N/A N/A N/A

0.3% of Beximco Pharmaceuticals shares are held by institutional investors. 4.2% of Beximco Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Beximco Pharmaceuticals has higher revenue and earnings than Amryt Pharma. Amryt Pharma is trading at a lower price-to-earnings ratio than Beximco Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousand0.03
Amryt Pharma£210.24M0.00N/A-£33.00N/A

In the previous week, Beximco Pharmaceuticals' average media sentiment score of 0.00 equaled Amryt Pharma'saverage media sentiment score.

Company Overall Sentiment
Beximco Pharmaceuticals Neutral
Amryt Pharma Neutral

Summary

Beximco Pharmaceuticals beats Amryt Pharma on 8 of the 8 factors compared between the two stocks.

How does Beximco Pharmaceuticals compare to Alliance Pharma?

Alliance Pharma (LON:APH) and Beximco Pharmaceuticals (LON:BXP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Beximco Pharmaceuticals has a net margin of 16.76% compared to Alliance Pharma's net margin of -6.00%. Beximco Pharmaceuticals' return on equity of 11.99% beat Alliance Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Alliance Pharma-6.00% -5.04% 5.98%
Beximco Pharmaceuticals 16.76%11.99%6.97%

Beximco Pharmaceuticals has higher revenue and earnings than Alliance Pharma. Alliance Pharma is trading at a lower price-to-earnings ratio than Beximco Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alliance Pharma£183.50M1.91-£33.65M-£6.20N/A
Beximco Pharmaceuticals£53.93B0.00£970.84B£1.94 thousand0.03

In the previous week, Alliance Pharma's average media sentiment score of 0.00 equaled Beximco Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Alliance Pharma Neutral
Beximco Pharmaceuticals Neutral

Alliance Pharma has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Beximco Pharmaceuticals has a beta of 0.248, suggesting that its stock price is 75% less volatile than the broader market.

66.3% of Alliance Pharma shares are owned by institutional investors. Comparatively, 0.3% of Beximco Pharmaceuticals shares are owned by institutional investors. 12.0% of Alliance Pharma shares are owned by insiders. Comparatively, 4.2% of Beximco Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Beximco Pharmaceuticals beats Alliance Pharma on 7 of the 11 factors compared between the two stocks.

Get Beximco Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BXP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BXP vs. The Competition

Export
MetricBeximco PharmaceuticalsPharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£240.90M£12.45B£7.27B£2.90B
Dividend Yield5.11%2.64%2.54%6.14%
P/E Ratio0.03784.87270.69367.91
Price / Sales0.00761.74639.8983,482.27
Price / CashN/A92.1276.8927.89
Price / Book0.0011.8513.437.17
Net Income£970.84B£2.80B£3.46B£5.89B
7 Day Performance-4.76%1.92%2.15%0.32%
1 Month Performance3.85%3.70%6.18%2.87%
1 Year Performance8.87%6.59%24.96%22.30%

Beximco Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BXP
Beximco Pharmaceuticals
N/AGBX 54
-1.8%		N/A+8.9%£240.90M£53.93B0.035,500
VEC
Vectura Group
N/AN/AN/AN/A£1.01B£190.60M8.209,200
ERGO
Ergomed
N/AN/AN/AN/A£701.00M£152.09M4,641.386
BMY
Bloomsbury Publishing
3.6206 of 5 stars		GBX 664
+2.6%		GBX 800
+20.5%		+34.2%£536.80M£325.90M20.2434,300
AMYT
Amryt Pharma
N/AN/AN/AN/A£457.11M£210.24MN/A290

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:BXP) was last updated on 8/22/2026 by MarketBeat.com Staff.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Your Free Report (Inside)
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
23,281 stocks. Only ONE survived.
One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...
Monument Traders Alliance | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
The world's #2 gold miner is running on fumes [it has to buy]
Barrick, the world's second-largest gold miner, produced 7.77 million ounces in 2010. This year, output is exp...
Golden Portfolio | Sponsoredtc pixel